Abstract 5699: Tegavivint directly targets TBL1 to inhibit b-catenin nuclear oncogenic activity
Aundrietta D. Duncan(Io Therapeutics (United States)), Stephen Horrigan, Prashi Jain, Julissa Simmons(Io Therapeutics (United States)), Elena Ramirez, Mahtab Youseffi
Cited by 0
Related Papers
TRIM24 Is a p53-Induced E3-Ubiquitin Ligase That Undergoes ATM-Mediated Phosphorylation and Autodegradation during DNA Damage
|Molecular and Cellular Biology|2014|106
Mammary-specific expression of Trim24 establishes a mouse model of human metaplastic breast cancer
|Nature Communications|2021|43
Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children
|European Journal of Cancer|2020|25
Sample Preparation for Mass Cytometry Analysis
|Journal of Visualized Experiments|2017|9
Seclidemstat blocks the transcriptional function of multiple FET-fusion oncoproteins
|bioRxiv (Cold Spring Harbor Laboratory)|2024|3